Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Fuel Cell Stocks Erupt: Bloom Energy Surges 23%, FuelCell Energy Rockets 32%, Plug Power Climbs 9% (24/7 Wall St.) +++ PLUG POWER Aktie +3,47%

REGENERON Aktie

 >REGENERON Aktienkurs 
582.9 EUR    -6.8%    (TradegateBSX)
Ask: 581.8 EUR / 110 Stück
Bid: 580.4 EUR / 110 Stück
Tagesumsatz: 203 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: -0,5%
1 Monat: -1,8%
3 Monate: +0,9%
6 Monate: +13,5%
1 Jahr: +18,8%
laufendes Jahr: -4,7%
>REGENERON Aktie
Name:  REGENERON PHARMAC.DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  http://www.regeneron.com/
Profil:  Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye dis..
>Volltext..
Marktkapitalisierung:  67187.18 Mio. EUR
Unternehmenswert:  62383.53 Mio. EUR
Umsatz:  12246.38 Mio. EUR
EBITDA:  3625.1 Mio. EUR
Nettogewinn:  3846.41 Mio. EUR
Gewinn je Aktie:  36.82 EUR
Schulden:  2538.18 Mio. EUR
Liquide Mittel:  2667.1 Mio. EUR
Operativer Cashflow:  4251.13 Mio. EUR
Bargeldquote:  1.97
Umsatzwachstum:  -10.98%
Gewinnwachstum:  -10.02%
Dividende je Aktie:  3.19 EUR
Dividendenrendite:  0.48%
Dividendenschätzung:  0.51%
Div. Historie:  20.02.26 - 0.798906€
20.11.25 - 0.76287204€
>weitere anzeigen...
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 77.727 USD.
Suchwörter:  REGENERON
Letzte Datenerhebung:  29.04.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 103.9 Mio. St.
Frei handelbar: 97.94%
Rückkaufquote: 3.56%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.79 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 17.8%
Bewertung:
KGV: 18.15
KGV lG: 16.51
KUV: 5.73
KBV: 2.55
PEG-Ratio: 2.15
EV/EBITDA: 17.21
Rentabilität:
Bruttomarge: 81.56%
Gewinnmarge: 31.41%
Operative Marge: 25.81%
Managementeffizenz:
Gesamtkaprendite: 11.49%
Eigenkaprendite: 14.87%
>REGENERON Peer Group
 
29.04.26 - 19:00
Regeneron (REGN) Q1 2026 Earnings Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 16:45
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
 
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....
29.04.26 - 16:24
Earnings Call Transkript: Regeneron übertrifft im ersten Quartal 2026 die Schätzungen, Aktie gibt dennoch nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 15:21
Regeneron drops despite Q1 beat, $3B share buyback program (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 15:15
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
 
Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...
29.04.26 - 13:01
Regeneron Pharmaceuticals Inc Reveals Drop In Q1 Bottom Line (AFX)
 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) reported a profit for first quarter that Drops, from the same period last yearThe company's earnings totaled $727.2 million, or $6.75 pe......
29.04.26 - 12:48
Regeneron beats first quarter estimates on Dupixent strength (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 12:36
Regeneron Pharmaceuticals Non-GAAP EPS of $9.47 beats by $0.57, revenue of $3.61B beats by $130M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 12:33
Regeneron Reports First Quarter 2026 Financial and Operating Results (GlobeNewswire EN)
 
TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update....
28.04.26 - 18:48
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.04.26 - 19:45
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN′s Q1 Earnings? (Zacks)
 
Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising competition....
24.04.26 - 21:18
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss (CNBC)
 
Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it will charge in other countries....
24.04.26 - 20:45
FDA Approves First Gene Therapy To Treat Deafness (ZeroHedge)
 
FDA Approves First Gene Therapy To Treat Deafness Authored by Zachary Stieber via The Epoch Times (emphasis ours), Federal regulators on Thursday approved the first gene therapy to restore hearing, just two months after the therapy's maker formally requested a license. Dr. Marty Makary, the Food and Drug Administration's commissioner, in an undated file photograph. Madalina Vasiliu/The Epoch Times The Food and Drug Administration approved the Regeneron therapy, Otarmeni, for children and adults with severe or profound hearing loss associated with OTOF gene variants. The approval came 61 days after Regeneron filed for a biologics license, under a new effort known as the Commissioner's National Priority Voucher Program that emphasizes quickly reviewing applications for products that address unmet needs. “Today's approval is a significant milestone in the treatment of genetic hearing loss,” Dr. Marty Makary, the FDA's commissioner, said in a statement. “Through the national priority vo...
24.04.26 - 18:36
Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It′s A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia (AFX)
 
NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multi......
24.04.26 - 16:45
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
 
Get a deeper insight into the potential performance of Regeneron (REGN) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics....
24.04.26 - 13:12
Regeneron Agrees To Lower Prescription Drug Prices Under MFN Deal (AFX)
 
WASHINGTON (dpa-AFX) - President Donald Trump has announced an MFN pricing deal with Regeneron to lower prescription drug prices that Americans pay for some of the world's most innovative drugs, i......
24.04.26 - 06:30
Regeneron Pharma: FDA Grants Approval For Otarmeni, Gene Therapy For Genetic Hearing Loss (AFX)
 
LONDON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the FDA has granted accelerated approval for Otarmeni, the first gene therapy and second new molecular entity approved under the FDA C......
23.04.26 - 21:48
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. (GlobeNewswire EN)
 
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S....
23.04.26 - 21:42
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free (CNBC)
 
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump....
23.04.26 - 19:48
FDA Approves First-Ever Gene Therapy to Restore Hearing (WSJ EN)
 
Regeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das Vergessen kann eine große produktive Tat sein. - Hans Arndt
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!